About Us

BiPar is a clinical-stage drug development company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients.  

BiPar is advancing the field of cancer therapy through the development of a novel investigational anticancer agent, BSI-201 (iniparib).  Iniparib is the United States Adopted Name (USAN) for this compound.  Iniparib is being evaluated in clinical trials in triple-negative breast cancer, ovarian cancer and other solid tumor cancers.

BiPar Sciences is a wholly-owned subsidiary of sanofi-aventis.